Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

New biologic for breast cancer receives advisory committee approval

Sep. 3, 1998

Phase I/II trial provides evidence of potential efficacy of ovarian cancer vaccine

Sep. 2, 1998

Medarex receives milestone payment from Merck KGaA

Sep. 2, 1998

Techniclone advancing development of Tumor Necrosis Therapy into phase II

Sep. 2, 1998

Pivotal clinical trial data for rituximab published

Aug. 28, 1998

Imutec receives patent protection for Virulizin in Canada

Aug. 24, 1998

Available from NIH: immunotoxin for the treatment of ovarian cancer and mesotheliomas

Aug. 20, 1998

BLP25 cancer vaccine enters phase I testing in patients with NSCLC

Aug. 19, 1998

Canadian patent covers Jenner's cancer vaccine

Aug. 13, 1998

Avax to begin pivotal trial with M-Vax in melanoma patients

July 31, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...